MedMira Inc. (MMIRF)
USD 0.02
(-70.43%)
USD 0.02
(-70.43%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.57 Million CAD | -47.79% |
| 2022 | -1.06 Million CAD | -675.95% |
| 2021 | 185.3 Thousand CAD | 116.45% |
| 2020 | -1.12 Million CAD | 11.79% |
| 2019 | -1.27 Million CAD | 26.83% |
| 2018 | -1.74 Million CAD | 17.37% |
| 2017 | -2.11 Million CAD | 48.72% |
| 2016 | -4.37 Million CAD | -73.26% |
| 2015 | -2.64 Million CAD | 23.03% |
| 2014 | -2.99 Million CAD | -28.12% |
| 2013 | -2.41 Million CAD | -12.6% |
| 2012 | -2.14 Million CAD | -65.28% |
| 2011 | -1.29 Million CAD | 43.77% |
| 2010 | -2.3 Million CAD | 7.28% |
| 2009 | -2.48 Million CAD | 22.96% |
| 2008 | -3.14 Million CAD | 3.81% |
| 2007 | -3.35 Million CAD | 36.37% |
| 2006 | -5.26 Million CAD | -21.55% |
| 2005 | -4.33 Million CAD | -37.15% |
| 2004 | -3.16 Million CAD | 20.29% |
| 2003 | -3.96 Million CAD | 17.2% |
| 2002 | -4.78 Million CAD | 24.37% |
| 2001 | -6.33 Million CAD | -112.11% |
| 2000 | -2.98 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -601.61 Thousand CAD | -14.19% |
| 2024 Q2 | -479.82 Thousand CAD | 11.44% |
| 2024 Q1 | -541.77 Thousand CAD | -24.01% |
| 2023 Q1 | -444.71 Thousand CAD | -80.39% |
| 2023 FY | - CAD | -47.79% |
| 2023 Q2 | -316.51 Thousand CAD | 28.83% |
| 2023 Q3 | -413 Thousand CAD | -30.49% |
| 2023 Q4 | -403.01 Thousand CAD | 2.42% |
| 2022 Q4 | -246.53 Thousand CAD | -1.57% |
| 2022 Q3 | -242.71 Thousand CAD | 20.82% |
| 2022 FY | - CAD | -675.95% |
| 2022 Q1 | -271.43 Thousand CAD | 34.94% |
| 2022 Q2 | -306.55 Thousand CAD | -12.94% |
| 2021 Q3 | -136.3 Thousand CAD | 34.07% |
| 2021 Q1 | 945.59 Thousand CAD | 4670.72% |
| 2021 Q2 | -206.76 Thousand CAD | -121.87% |
| 2021 FY | - CAD | 116.45% |
| 2021 Q4 | -417.21 Thousand CAD | -206.08% |
| 2020 Q1 | -236.08 Thousand CAD | 23.02% |
| 2020 Q3 | -484.97 Thousand CAD | -26.02% |
| 2020 Q2 | -384.84 Thousand CAD | -63.01% |
| 2020 FY | - CAD | 11.79% |
| 2020 Q4 | -20.68 Thousand CAD | 95.73% |
| 2019 FY | - CAD | 26.83% |
| 2019 Q1 | -296.56 Thousand CAD | -3.5% |
| 2019 Q2 | -367.92 Thousand CAD | -24.06% |
| 2019 Q3 | -305 Thousand CAD | 17.1% |
| 2019 Q4 | -306.68 Thousand CAD | -0.55% |
| 2018 Q1 | -513.22 Thousand CAD | -20.68% |
| 2018 FY | - CAD | 17.37% |
| 2018 Q4 | -286.53 Thousand CAD | 42.53% |
| 2018 Q3 | -498.53 Thousand CAD | 4.4% |
| 2018 Q2 | -521.47 Thousand CAD | -1.61% |
| 2017 Q2 | -402.36 Thousand CAD | 41.21% |
| 2017 FY | - CAD | 48.72% |
| 2017 Q4 | -425.29 Thousand CAD | 29.15% |
| 2017 Q3 | -600.28 Thousand CAD | -49.19% |
| 2017 Q1 | -684.44 Thousand CAD | 57.94% |
| 2016 Q1 | -685.63 Thousand CAD | -817.51% |
| 2016 FY | - CAD | -73.26% |
| 2016 Q2 | -790.39 Thousand CAD | -15.28% |
| 2016 Q3 | -1.01 Million CAD | -28.5% |
| 2016 Q4 | -1.62 Million CAD | -60.23% |
| 2015 Q4 | -74.72 Thousand CAD | 88.52% |
| 2015 Q3 | -650.74 Thousand CAD | 29.15% |
| 2015 FY | - CAD | 23.03% |
| 2015 Q2 | -918.49 Thousand CAD | -27.16% |
| 2015 Q1 | -722.33 Thousand CAD | -119.36% |
| 2014 Q4 | -329.29 Thousand CAD | 67.15% |
| 2014 FY | - CAD | -28.12% |
| 2014 Q3 | -1 Million CAD | 13.28% |
| 2014 Q1 | -586.95 Thousand CAD | -662.02% |
| 2014 Q2 | -1.15 Million CAD | -96.94% |
| 2013 Q4 | 104.43 Thousand CAD | 113.72% |
| 2013 Q2 | -531.27 Thousand CAD | -13.21% |
| 2013 Q1 | -469.29 Thousand CAD | 21.35% |
| 2013 Q3 | -761.04 Thousand CAD | -43.25% |
| 2013 FY | - CAD | -12.6% |
| 2012 FY | - CAD | -65.28% |
| 2012 Q1 | -164.62 Thousand CAD | -219.3% |
| 2012 Q2 | -1.05 Million CAD | -541.07% |
| 2012 Q4 | -596.66 Thousand CAD | -9.86% |
| 2012 Q3 | -543.12 Thousand CAD | 48.54% |
| 2011 Q4 | 137.99 Thousand CAD | 136.52% |
| 2011 FY | - CAD | 43.77% |
| 2011 Q2 | -614.44 Thousand CAD | -39.41% |
| 2011 Q1 | -440.75 Thousand CAD | 56.93% |
| 2011 Q3 | -377.89 Thousand CAD | 38.5% |
| 2010 FY | - CAD | 7.28% |
| 2010 Q4 | -1.02 Million CAD | -323.65% |
| 2010 Q3 | -241.53 Thousand CAD | 53.53% |
| 2010 Q2 | -519.74 Thousand CAD | -0.42% |
| 2010 Q1 | -517.57 Thousand CAD | 36.37% |
| 2009 Q3 | -463.48 Thousand CAD | 31.27% |
| 2009 Q2 | -674.38 Thousand CAD | -26.45% |
| 2009 Q1 | -533.33 Thousand CAD | 57.69% |
| 2009 FY | - CAD | 22.96% |
| 2009 Q4 | -813.36 Thousand CAD | -75.49% |
| 2008 Q1 | -691.2 Thousand CAD | 24.3% |
| 2008 FY | - CAD | 3.81% |
| 2008 Q4 | -1.26 Million CAD | -106.11% |
| 2008 Q3 | -611.63 Thousand CAD | -23.49% |
| 2008 Q2 | -495.3 Thousand CAD | 28.34% |
| 2007 Q4 | -913.03 Thousand CAD | -73.77% |
| 2007 Q2 | -923.58 Thousand CAD | 6.54% |
| 2007 FY | - CAD | 36.37% |
| 2007 Q3 | -525.41 Thousand CAD | 43.11% |
| 2007 Q1 | -988.25 Thousand CAD | 40.09% |
| 2006 Q3 | -1.67 Million CAD | -144.69% |
| 2006 Q4 | -1.64 Million CAD | 1.59% |
| 2006 FY | - CAD | -21.55% |
| 2006 Q1 | -1.25 Million CAD | 12.58% |
| 2006 Q2 | -685.03 Thousand CAD | 45.56% |
| 2005 Q1 | -836.35 Thousand CAD | -37.63% |
| 2005 Q2 | -1.02 Million CAD | -22.58% |
| 2005 Q3 | -1.03 Million CAD | -0.87% |
| 2005 Q4 | -1.43 Million CAD | -39.2% |
| 2005 FY | - CAD | -37.15% |
| 2004 Q2 | -869.57 Thousand CAD | -11.64% |
| 2004 Q4 | -607.67 Thousand CAD | 32.81% |
| 2004 FY | - CAD | 20.29% |
| 2004 Q1 | -778.89 Thousand CAD | -20.43% |
| 2004 Q3 | -904.47 Thousand CAD | -4.01% |
| 2003 Q2 | -958.34 Thousand CAD | -10.66% |
| 2003 Q4 | -646.75 Thousand CAD | 56.69% |
| 2003 Q3 | -1.49 Million CAD | -55.81% |
| 2003 FY | - CAD | 17.2% |
| 2003 Q1 | -866 Thousand CAD | 55.16% |
| 2002 Q2 | -778.34 Thousand CAD | 31.22% |
| 2002 Q1 | -1.13 Million CAD | 0.0% |
| 2002 FY | - CAD | 24.37% |
| 2002 Q3 | -947.47 Thousand CAD | -21.73% |
| 2002 Q4 | -1.93 Million CAD | -103.83% |
| 2001 FY | - CAD | -112.11% |
| 2000 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | 9.872% |
| Skye Bioscience, Inc. | -13.54 Million USD | 88.358% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.677% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 399.041% |
| Qrons Inc. | -40.08 Thousand USD | -3835.129% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 79.119% |
| CSL Limited | 4.78 Billion USD | 100.033% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 90.92% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 59.395% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -68.338% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.15% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -329.507% |
| Rebus Holdings, Inc. | -951 Thousand USD | -65.851% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -149.403% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 90.061% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 97.78% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 73.397% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -559.519% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.541% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 40.357% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2.682% |
| Mesoblast Limited | -62.38 Million USD | 97.472% |
| Marizyme, Inc. | -34.28 Million USD | 95.399% |
| Genus plc | 73.7 Million USD | 102.14% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 76.144% |
| Pharming Group N.V. | 9.87 Million USD | 115.969% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -6.039% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 55.533% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 82.02% |
| ContraFect Corporation | -64.99 Million USD | 97.573% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 65.153% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -12.515% |
| IMV Inc. | -35.52 Million USD | 95.56% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 32.127% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -204.459% |
| ONE Bio Corp. | 13.61 Million USD | 111.586% |
| Accustem Sciences Inc. | -3.74 Million USD | 57.9% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 96.73% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -24.473% |
| Q BioMed Inc. | -617.62 Thousand USD | -155.37% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 144.156% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 30.959% |
| Biomind Labs Inc. | -1.03 Million USD | -52.457% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.021% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 45.468% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 77.975% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 23556.856% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -6208.956% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 36.96% |
| GB Sciences, Inc. | -1.41 Million USD | -11.082% |
| Alpha Cognition Inc. | -9.7 Million USD | 83.749% |
| HST Global, Inc. | -5303.00 USD | -29642.391% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 23.323% |
| Halberd Corporation | -74.27 Thousand USD | -2023.398% |
| Enzolytics Inc. | -2.12 Million USD | 25.673% |
| Agentix Corp. | -1.37 Million USD | -14.98% |
| Resverlogix Corp. | -11.74 Million USD | 86.568% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 48.507% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 99.27% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 229.601% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 117.814% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -5.226% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 516.329% |
| AVAX Technologies, Inc. | -6.11 Million USD | 74.197% |
| Zenith Capital Corp. | -8.6 Million USD | 81.673% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.366% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8953.665% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 35.53% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -796.035% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 17.891% |
| Kadimastem Ltd | -2.62 Million USD | 39.901% |
| Helix BioMedix, Inc. | -1.04 Million USD | -50.743% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -770.979% |
| LadRx Corporation | 412.28 Thousand USD | 482.562% |
| Cell Source, Inc. | -4.27 Million USD | 63.084% |
| Regen BioPharma, Inc. | 1.46 Million USD | 207.591% |
| NovAccess Global Inc. | -1.03 Million USD | -52.42% |
| Affymax, Inc. | -14.29 Million USD | 88.966% |
| Itoco Inc. | -1.86 Million USD | 15.61% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -315.478% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -41.33% |
| Mobile Lads Corp. | -2.24 Million USD | 29.624% |
| CytoDyn Inc. | -18.02 Million USD | 91.252% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1895.772% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -12797.53% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -224.75% |
| SYBLEU INC | -141.57 Thousand USD | -1014.098% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -48.515% |
| International Stem Cell Corporation | 202 Thousand USD | 880.811% |
| Bioxytran, Inc. | -3.82 Million USD | 58.713% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2896.275% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 35.935% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 95.603% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3404.976% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 42.394% |
| Neutra Corp. | -181.24 Thousand USD | -770.215% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 92.176% |
| PureTech Health plc | -11.62 Million USD | 86.435% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 92.175% |
| IXICO plc | -707 Thousand USD | -123.089% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 79.476% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 96.738% |
| CSL Limited | 4.73 Billion USD | 100.033% |
| Cellectis S.A. | -92.63 Million USD | 98.297% |